Posted by Michael Wonder on 27 Nov 2016
Neurocrine announces Ingrezza (valbenazine) new drug application for the treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA
11 October 2016 - Neurocrine Biosciences today announced that the U.S. FDA has accepted for priority review the new drug application for Ingrezza (valbenazine) for the treatment of tardive dyskinesia.
The Ingrezza application has been given a Prescription Drug User Fee Act target action date of 11 April 2017.
